{ "company_number": "11463856", "name": "Pandeia Therapeutics Limited", "url": "/company/11463856", "status": "Active", "is_active": true, "company_type": "Private Limited Company", "incorporated_on": "2018-07-13", "dissolved_on": null, "sic_codes": [ { "code": "72110", "description": "Research and experimental development on biotechnology", "section": "M", "section_name": "Professional, scientific and technical activities", "url": "/sic/72110" } ], "registered_address": { "id": 1501757, "url": "/address/1501757", "line1": "THE CAMBRIDGE PARTNERSHIP THE DOROTHY HODGKIN BLDG BABRAHAM RESEARCH CAMPUS", "line2": "BABRAHAM", "post_town": "CAMBRIDGE", "county": "", "country": "ENGLAND", "postcode": "CB22 3FH" }, "companies_house_url": "https://find-and-update.company-information.service.gov.uk/company/11463856", "previous_names": [], "care_of": "", "po_box": "", "country_of_origin": "United Kingdom", "accounts": { "next_due": "2026-09-30", "last_made_up": "2024-12-31", "category": "SMALL", "filings": [ { "url": "/company/11463856/accounts/2024-12-31", "pdf_url": "/company/11463856/accounts/2024-12-31.pdf", "made_up_date": "2024-12-31", "period_start": "2024-12-31", "period_end": "2024-12-31", "entity_name": "Pandeia Therapeutics Limited", "dormant": false, "average_employees": "1.00", "tangible_fixed_assets": null, "debtors": "47529.00", "cash_bank_in_hand": "222751.00", "current_assets": "270280.00", "creditors_due_within_one_year": null, "creditors_due_after_one_year": null, "net_current_assets_liabilities": "142427.00", "total_assets_less_current_liabilities": "142427.00", "net_assets_liabilities": "-3214073.00", "called_up_share_capital": null, "profit_loss_account_reserve": null, "shareholder_funds": "5062.00", "turnover": null, "other_operating_income": null, "cost_sales": null, "gross_profit_loss": null, "administrative_expenses": null, "raw_materials_consumables": null, "staff_costs": null, "depreciation_written_off": null, "other_operating_charges": null, "operating_profit_loss": null, "profit_before_tax": null, "tax_on_profit": null, "profit_loss_for_period": null, "file_type": "html", "parse_error": "", "source_zip": "Accounts_Monthly_Data-September2025.zip" }, { "url": "/company/11463856/accounts/2023-12-31", "pdf_url": "/company/11463856/accounts/2023-12-31.pdf", "made_up_date": "2023-12-31", "period_start": "2023-12-31", "period_end": "2023-12-31", "entity_name": "Pandeia Therapeutics Limited", "dormant": false, "average_employees": "3.00", "tangible_fixed_assets": "343.00", "debtors": "258204.00", "cash_bank_in_hand": "178617.00", "current_assets": "436821.00", "creditors_due_within_one_year": null, "creditors_due_after_one_year": null, "net_current_assets_liabilities": "275035.00", "total_assets_less_current_liabilities": "275378.00", "net_assets_liabilities": "-1295422.00", "called_up_share_capital": null, "profit_loss_account_reserve": null, "shareholder_funds": "5062.00", "turnover": null, "other_operating_income": null, "cost_sales": null, "gross_profit_loss": null, "administrative_expenses": null, "raw_materials_consumables": null, "staff_costs": null, "depreciation_written_off": null, "other_operating_charges": null, "operating_profit_loss": null, "profit_before_tax": null, "tax_on_profit": null, "profit_loss_for_period": null, "file_type": "html", "parse_error": "", "source_zip": "Accounts_Monthly_Data-September2024.zip" }, { "url": "/company/11463856/accounts/2022-08-31", "pdf_url": "/company/11463856/accounts/2022-08-31.pdf", "made_up_date": "2022-08-31", "period_start": "2022-08-31", "period_end": "2022-08-31", "entity_name": "Pandeia Therapeutics Limited", "dormant": false, "average_employees": "3.00", "tangible_fixed_assets": "957.00", "debtors": "280123.00", "cash_bank_in_hand": "796269.00", "current_assets": "1076392.00", "creditors_due_within_one_year": null, "creditors_due_after_one_year": null, "net_current_assets_liabilities": "828645.00", "total_assets_less_current_liabilities": "829602.00", "net_assets_liabilities": null, "called_up_share_capital": null, "profit_loss_account_reserve": null, "shareholder_funds": "5062.00", "turnover": null, "other_operating_income": null, "cost_sales": null, "gross_profit_loss": null, "administrative_expenses": null, "raw_materials_consumables": null, "staff_costs": null, "depreciation_written_off": null, "other_operating_charges": null, "operating_profit_loss": null, "profit_before_tax": null, "tax_on_profit": null, "profit_loss_for_period": null, "file_type": "html", "parse_error": "", "source_zip": "Accounts_Monthly_Data-October2022.zip" }, { "url": "/company/11463856/accounts/2021-12-31", "pdf_url": "/company/11463856/accounts/2021-12-31.pdf", "made_up_date": "2021-12-31", "period_start": "2021-12-31", "period_end": "2021-12-31", "entity_name": "Pandeia Therapeutics Limited", "dormant": false, "average_employees": "3.00", "tangible_fixed_assets": "1263.00", "debtors": "219023.00", "cash_bank_in_hand": "1525884.00", "current_assets": "1744907.00", "creditors_due_within_one_year": null, "creditors_due_after_one_year": null, "net_current_assets_liabilities": "1628569.00", "total_assets_less_current_liabilities": "1629832.00", "net_assets_liabilities": null, "called_up_share_capital": null, "profit_loss_account_reserve": null, "shareholder_funds": "5062.00", "turnover": null, "other_operating_income": null, "cost_sales": null, "gross_profit_loss": null, "administrative_expenses": null, "raw_materials_consumables": null, "staff_costs": null, "depreciation_written_off": null, "other_operating_charges": null, "operating_profit_loss": null, "profit_before_tax": null, "tax_on_profit": null, "profit_loss_for_period": null, "file_type": "html", "parse_error": "", "source_zip": "Accounts_Monthly_Data-March2022.zip" }, { "url": "/company/11463856/accounts/2020-12-31", "pdf_url": "/company/11463856/accounts/2020-12-31.pdf", "made_up_date": "2020-12-31", "period_start": "2020-12-31", "period_end": "2020-12-31", "entity_name": "Pandeia Therapeutics Limited", "dormant": false, "average_employees": "1.00", "tangible_fixed_assets": "1722.00", "debtors": "513110.00", "cash_bank_in_hand": "364357.00", "current_assets": "877467.00", "creditors_due_within_one_year": null, "creditors_due_after_one_year": null, "net_current_assets_liabilities": "743356.00", "total_assets_less_current_liabilities": "745078.00", "net_assets_liabilities": null, "called_up_share_capital": null, "profit_loss_account_reserve": null, "shareholder_funds": "3041.00", "turnover": null, "other_operating_income": null, "cost_sales": null, "gross_profit_loss": null, "administrative_expenses": null, "raw_materials_consumables": null, "staff_costs": null, "depreciation_written_off": null, "other_operating_charges": null, "operating_profit_loss": null, "profit_before_tax": null, "tax_on_profit": null, "profit_loss_for_period": null, "file_type": "html", "parse_error": "", "source_zip": "Accounts_Monthly_Data-February2021.zip" }, { "url": "/company/11463856/accounts/2019-12-31", "pdf_url": "/company/11463856/accounts/2019-12-31.pdf", "made_up_date": "2019-12-31", "period_start": "2019-12-31", "period_end": "2019-12-31", "entity_name": "Pandeia Therapeutics Limited", "dormant": false, "average_employees": "1.00", "tangible_fixed_assets": "2182.00", "debtors": "175664.00", "cash_bank_in_hand": "1385926.00", "current_assets": "1561590.00", "creditors_due_within_one_year": null, "creditors_due_after_one_year": null, "net_current_assets_liabilities": "1404547.00", "total_assets_less_current_liabilities": "1406729.00", "net_assets_liabilities": null, "called_up_share_capital": null, "profit_loss_account_reserve": null, "shareholder_funds": "2196.00", "turnover": null, "other_operating_income": null, "cost_sales": null, "gross_profit_loss": null, "administrative_expenses": null, "raw_materials_consumables": null, "staff_costs": null, "depreciation_written_off": null, "other_operating_charges": null, "operating_profit_loss": null, "profit_before_tax": null, "tax_on_profit": null, "profit_loss_for_period": null, "file_type": "html", "parse_error": "", "source_zip": "Accounts_Monthly_Data-March2020.zip" } ], "pdf_only_filings": [], "filing_history_url": "https://find-and-update.company-information.service.gov.uk/company/11463856/filing-history" }, "confirmation_statement": { "next_due": "2027-07-10", "last_made_up": "2026-06-26" }, "officers": [], "psc": [ { "name": "Mr Martin Quibell", "kind": "individual-person-with-significant-control", "person_url": "/person/3185690", "controlling_company_url": null, "natures_of_control": [ "ownership-of-shares-25-to-50-percent", "voting-rights-25-to-50-percent", "right-to-appoint-and-remove-directors" ], "notified_on": "2019-03-05", "ceased_on": "2019-03-05", "nationality": "British", "country_of_residence": "England", "source": "snapshot" }, { "name": "Dr Fraser Murray", "kind": "individual-person-with-significant-control", "person_url": "/person/1599347", "controlling_company_url": null, "natures_of_control": [ "ownership-of-shares-25-to-50-percent", "voting-rights-25-to-50-percent", "right-to-appoint-and-remove-directors" ], "notified_on": "2019-03-05", "ceased_on": "2019-03-05", "nationality": "British", "country_of_residence": "England", "source": "snapshot" }, { "name": "Dr Timothy Schulz-Utermoehl", "kind": "individual-person-with-significant-control", "person_url": "/person/5042239", "controlling_company_url": null, "natures_of_control": [ "ownership-of-shares-75-to-100-percent", "voting-rights-75-to-100-percent", "right-to-appoint-and-remove-directors" ], "notified_on": "2018-07-13", "ceased_on": "2019-09-20", "nationality": "German", "country_of_residence": "England", "source": "snapshot" }, { "name": "Medicxi Ventures I Lp", "kind": "corporate-entity-person-with-significant-control", "person_url": null, "controlling_company_url": null, "natures_of_control": [ "ownership-of-shares-75-to-100-percent" ], "notified_on": "2019-09-20", "ceased_on": "2022-12-22", "nationality": "", "country_of_residence": "", "source": "snapshot" }, { "name": "Acadia Pharmaceuticals Inc.", "kind": "corporate-entity-person-with-significant-control", "person_url": null, "controlling_company_url": null, "natures_of_control": [ "ownership-of-shares-75-to-100-percent" ], "notified_on": "2022-12-22", "ceased_on": null, "nationality": "", "country_of_residence": "", "source": "snapshot" } ], "external_links": [], "provenance": { "source": "snapshot", "first_seen_at": "2026-07-05T12:35:35.811816+00:00", "last_seen_snapshot": "2026-09-01", "retrieved_at": "2026-09-27T03:25:12.661406+00:00" }, "licence": "Open Government Licence v3.0", "licence_url": "https://www.nationalarchives.gov.uk/doc/open-government-licence/version/3/", "attribution": "Contains public sector information licensed under the Open Government Licence v3.0. Source: Companies House." }